All suffers responded positively to local injections of BoNT/A that resulted in less headaches and precranial muscle tenderness (Dolly and O’Connell, 2012) (Relja and Telarovic, 2004). Furthermore, Epigenetics inhibitor Elza compared BoNT/A

with other currently available drugs for the treatment of migraines. Their results suggested that the BoNT/A was more effective for the group of patients with frequent episodic migraines. However, considering the clinical benefits and the lack of undesirable side effects such as weight gain and constipation, they argued that BoNT/A should be considered for use in the patients with chronic headaches as an alternative therapy or in patients with contraindications for the use of other classes of drugs. They also reminded that further investigation is needed to define patient subgroups that might benefit from BoNT/A (Magalhães et al., 2010). Arthritis is an important and growing public health problem (Lawrence et al., 2008), There is a growing need for novel treatments of refractory arthritis joint pain as aging

population is expanding with many sufferers who cannot receive the joint replacement surgery. In 2008, Jasvinder et al. reported the use of intra-articular BoNT/A in two rheumatoid arthritis (RA) patients with persistent painful monoarthritis in ankle/feet joints. Both patients had monaticular learn more pain despite a good response of all other joints to a combination therapy that also included anti-tumor necrosis factor therapy. All intra-articular corticosteroid injections and declined surgical options were failed in both patients. They began with a single “off-label” intra-articular injection of BoNT/A into the right ankle (100 units) and left first metatarsophalangeal joint (25 units). As a result, their Paclitaxel cell line pain and function improved significantly

(>40%) in both patients and the function lasted 15–18 months. They concluded that the intra-articular BoNT/A may provide an additional therapeutic option in RA patients with persistent monoarthritis (Singh and Mahowald, 2009). In 2009, Maren et al. conducted several small open label studies in which they injected BoNT/A into the joints with arthritis. They found that two third of the patients had more than 50% reduction in the joint pain severity that was associated with a significant improvement in function. Importantly, no serious adverse effects of BoNT/A were reported. They continued their studies using the same method in shoulders and knees. The results showed that BoNT/A produced a significant decrease in shoulder pain severity in one month (6.8–4.4 on VAS, p = 0.22). Furthermore, BoNT/A produced a significant 48% decrease in McGill Total Pain Score in the knees in one month (p = 0.11). This was still significant three months after the injection (p = 0.02).